

Sitagliptin Increases the Serum Level of HDL

Daneshjou D^{1*}, Soleimani Mehranjani M¹, Shariatzadeh SMA¹, Zadehmodarres Sh²

1. Department of Biology, Faculty of Science, Arak University, Arak, Iran.

2. Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Email: d.daneshjou@yahoo.com

Introduction

Abnormal lipid profile patterns are common in patients with polycystic ovarian syndrome, and these abnormalities are not uniform in all populations(1). Dyslipidemia in PCOS may characterize by elevated plasma levels of cholesterol, low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), triglycerides (TG), and reduced concentration of high-density lipoproteins (HDL)(2). Insights into the relationship between insulin resistance and development of PCOS led to the use of insulin sensitizing agents(3). The most popular of these agents is metformin. Also, sitagliptin, as an oral antihyperglycemic agent, is used in the treatment of diabetes mellitus type2, and recently is considered in the clinical investigations of PCOS(4, 5). The aim of the present study was to evaluate the effect of sitagliptin and metformin on the lipid profile in patients with PCOS.

Method and Material

In this clinical trial, 60 infertile PCOS patients were selected based on the Rotterdam criteria; Then they divided into 3 groups (n=20): metformin group (Glucophage, Merck, West Drayton, UK; 500 mg, twice a day), sitagliptin group (Januvia, Merck, West Drayton, UK; 50 mg, twice a day) and placebo group. All patients were undergoing treatment with antagonist GnRH protocol. Treatment was carried out two months before the start of the ovulation cycle and continued until the day of oocyte aspiration. At the day of ovum pick up, lipid profile in blood serum were assayed.

Result

The serum levels of HDL had significant difference in the sitagliptin group compared to the placebo (54.38±4.78 vs. 9.59±6.18, p=0.03). There were no significant differences in serum levels of cholesterol, TG, LDL and VLDL among the groups (p>0.05) (Figure1).




Fig.1: Distribution of lipid profile in PCOS patients undergoing treatment of metformin, sitagliptin and placebo. Means with different letter code have significant difference and means with similar letter code have no significant difference with each other

Conclusion

This study shows, sitagliptin can improve HDL levels more effectively than metformin in patients with PCOS undergoing ICSI.

References

- 1- Kiranmayee, D., Kavya, K., Himabindu, Y., Sriharibabu, M., Madhuri, G. L. J., & Venu, S. (2017). Correlations between anthropometry and lipid profile in women with PCOS. *Journal of human reproductive sciences*, 10(3), 167.
- 2- Valkenburg, O., Steegers-Theunissen, R. P., Smedts, H. P., Dallinga-Thie, G. M., Fauser, B. C., Westerveld, E. H., & Laven, J. S. (2008). A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. *The Journal Of Clinical Endocrinology & Metabolism*, 93(2), 470-476.
- 3- Dunaif, A. (2008). Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal. *Nature Clinical Practice Endocrinology & Metabolism*, 4(5), 272-283.
- 4- Daneshjou, D., Modarres, S. Z., & Mehranjani, M. S. (2020). Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI. *Irish Journal of Medical Science (1971-)*, 1-8.
- 5- Palma, J. P., Byhen, E. L., Ibáñez, L., Macedo, L. B., Palma, C. P., & Velázquez, C. R. (2018). Comparative treatment between sitagliptin vs. metformin, alone or in combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for developing diabetes mellitus and gestational diabetes: A pilot study. *Revista Médica del Hospital General de México*, 81(1), 15-26.

Acknowledgement

The authors thank the infertility clinic of Mahdiyeh educational hospital (Tehran, Iran) and also the research laboratory of Arak University (Arak, Iran). This study was financially supported by the Arak University and the Men's Health and Reproductive Health Research Center of Shahid Beheshti University of Medical Sciences.